Senti Biosciences Gross Margin

What does Senti Biosciences do? Senti Biosciences develops cell and gene therapies using its gene circuit platform, targeting diseases like cancer. The company's products SENTI-202, SENTI-401, and SENTI-301A are designed for specific treatments: SENTI-202 is an off-the-shelf CAR-NK therapy targeting cancer while sparing bone marrow, SENTI-401 addresses colorectal cancer and solid tumors, and SENTI-301A targets hepatocellular carcinoma and other solid tumors. The gene circuit platform is modality-agnostic, applicable to NK cells, T cells, TILs, stem cells, and in vivo gene therapies like AAV and mRNA. The firm generates revenue through the development and potential commercialization of its therapeutic candidates. SENTI-202, SENTI-401, and SENTI-301A are in development stages, with SENTI-202 focusing on Logic Gated (OR + NOT) CAR-NK cell therapy. The company targets oncology segments, particularly for cancer treatments requiring precise targeting mechanisms. Its platform technology enables flexible application across various cell types and therapeutic modalities. Senti Biosciences' business model relies on advancing its pipeline candidates toward clinical trials and eventual market entry. The company's focus on engineered therapies using gene circuits positions it within the biotechnology sector, targeting specific disease areas with innovative approaches. The development of these therapies is intended to address unmet medical needs in oncology. Senti Biosciences is one of the most popular companies on Eulerpool.